SRP3010
BCMA human
recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sinónimos:
B-Cell Maturation Antigen, BCM, TNFRSF17
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Código UNSPSC:
12352202
NACRES:
NA.32
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Productos recomendados
origen biológico
human
recombinante
expressed in E. coli
Ensayo
≥98% (HPLC)
≥98% (SDS-PAGE)
Formulario
lyophilized
mol peso
5.3 kDa
envase
pkg of 20 μg
técnicas
cell culture | mammalian: suitable
impurezas
<0.1 EU/μg endotoxin, tested
Nº de acceso UniProt
Condiciones de envío
wet ice
temp. de almacenamiento
−20°C
Información sobre el gen
human ... TNFRSF17(608)
Descripción general
B-cell maturation antigen (BCMA) or tumor necrosis factor receptor superfamily member 17(TNFRSF17), a member of the tumor necrosis factor (TNF) receptor superfamily, binds to B-cell–activating factor (BAFF) and a proliferation-inducing ligand (APRIL). BCMA is expressed on mature B-cells and other B-cell lines.[1][2] The human BCMA gene codes for a 184 amino acid type I transmembrane protein, which contains a 54 amino acid extracellular domain, a 23 amino acid transmembrane domain, and a 107 amino acid cytoplasmic domain. Recombinant soluble human BCMA is a 50 amino acid polypeptide (5.3kDa) comprising the TNFR homologous region of the BCMA protein.
Acciones bioquímicas o fisiológicas
B-cell maturation antigen (BCMA) or tumor necrosis factor receptor superfamily member 17 (TNFRSF17) plays an important role in B cell development, function and regulation. BCMA also has the capability to activate nuclear factor-κB (NF-κB), janus kinase (JNK) and mitogen activated protein kinases (MAPKs). The protein is expressed in certain cancers like glioblastoma, chronic lymphocytic leukemia, Hodgkin lymphoma and multiple myeloma. It has a role in the maintenance of survival of long-lived plasma cells in bone marrow.[3]
Secuencia
AGQCSQNEYF DSLLHACIPC QLRCSSNTPP LTCQRYCNAS VTNSVKGTNA
Forma física
Lyophilized with no additives.
Reconstitución
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 3
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells.
Yang M
Journal of Immunology, 175(5), 2814-2824 (2005)
Christine M Coquery et al.
Critical reviews in immunology, 32(4), 287-305 (2012-12-15)
B cell maturation antigen (BCMA) is a tumor necrosis family receptor (TNFR) member that is predominantly expressed on terminally differentiated B cells and, upon binding to its ligands B cell activator of the TNF family (BAFF) and a proliferation inducing
P Rennert et al.
The Journal of experimental medicine, 192(11), 1677-1684 (2000-12-06)
A proliferation-inducing ligand (APRIL) is a ligand of the tumor necrosis factor (TNF) family that stimulates tumor cell growth in vitro and in vivo. Expression of APRIL is highly upregulated in many tumors including colon and prostate carcinomas. Here we
Han-Wen Huang et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(27), 10928-10933 (2013-06-19)
Glycosylation, an important posttranslational modification process, can modulate the structure and function of proteins, but its effect on the properties of plasma cells is largely unknown. In this study, we identified a panel of glycoproteins by click reaction with alkynyl
Liang Lin et al.
Leukemia, 35(3), 752-763 (2020-07-08)
Chimeric antigen receptor (CAR) T-cell therapy remains limited to select centers that can carefully monitor adverse events. To broaden use of CAR T cells in community clinics and in a frontline setting, we developed a novel CD8+ CAR T-cell product
Active Filters
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico
